GILD Quote, Trading Chart, Gilead Sciences Inc.
home / stock / gild / gild quote
$65.24 Last:
0.96% Change Percent:
$64.51 Open:
$65.24 Previous Close:
$65.35 High:
$63.96 Low:
2,356,288 Volume:
03/08/2021 11:10:19 am Last Trade Date Time:
Quotes are delayed by 15 to 20 minutes.
Last Five Trading Days
| Stock Date | Open Price | Close Price | High | Low | Volume |
|---|---|---|---|---|---|
| 2021-03-08 | 64.51 | 65.24 | 65.35 | 63.96 | 2,356,288 |
| 2021-03-05 | 63.42 | 64.62 | 64.745 | 63.3 | 9,748,500 |
| 2021-03-04 | 62.8 | 63.23 | 64.54 | 62.53 | 15,745,171 |
| 2021-03-03 | 62.7889 | 62.75 | 63.32 | 62.17 | 7,032,406 |
| 2021-03-02 | 62.495 | 63.01 | 63.59 | 62.35 | 6,836,236 |
| 2021-03-01 | 61.76 | 62.46 | 62.63 | 61.65 | 7,326,219 |
| 2021-02-26 | 62.78 | 61.4 | 62.79 | 61.39 | 10,387,737 |
| 2021-02-25 | 63.77 | 62.79 | 63.97 | 62.51 | 7,663,682 |
| 2021-02-24 | 63.56 | 63.71 | 64.23 | 62.81 | 6,523,061 |
| 2021-02-23 | 63.85 | 63.68 | 64.16 | 62.78 | 8,701,996 |
| 2021-02-22 | 63.93 | 64.11 | 64.47 | 63.525 | 6,552,037 |
| 2021-02-19 | 65.08 | 64.37 | 65.22 | 64.27 | 6,030,512 |
| 2021-02-18 | 64.86 | 65.23 | 65.46 | 64.33 | 6,102,297 |
| 2021-02-17 | 64.3335 | 65.1 | 65.14 | 63.84 | 7,691,487 |
| 2021-02-16 | 66.41 | 64.8 | 66.6 | 64.52 | 9,707,988 |
| 2021-02-15 | 66.78 | 66.89 | 67.27 | 66.36 | 3,977,653 |
| 2021-02-12 | 66.78 | 66.89 | 67.27 | 66.36 | 3,967,202 |
| 2021-02-11 | 67.2 | 66.92 | 67.2 | 66.05 | 5,778,925 |
| 2021-02-10 | 67.26 | 67.29 | 68.32 | 67.1 | 7,572,231 |
| 2021-02-09 | 67.77 | 67.3 | 67.84 | 66.8504 | 6,605,884 |
News, Short Squeeze, Breakout and More Instantly...
-
-- Use of Corticosteroids Prior to Yescarta Infusion Has the Potential to Impact the Benefit/Risk Profile Based on Data from a Cohort of ZUMA-1 Patients -- -- Response Rates Observed in New Analysis Remain Consistent with Pivotal Cohorts -- Kite, a Gilead Com...
-
A large part of a $5 billion bet that Gilead Sciences (NASDAQ: GILD) made in 2019 has fallen apart in late clinical-stage development. The bottom fell out from under ziritaxestat, a new drug candidate Gilead Sciences was developing in partnership with Galapagos (NASDAQ: GLPG) ...
-
Galapagos NV (Euronext & Nasdaq: GLPG) and Gilead Sciences (Nasdaq: GILD) today announced the decision to halt the ISABELA Phase 3 clinical studies with the investigational autotaxin inhibitor ziritaxestat in patients with idiopathic pulmonary fibrosis. The decision is based on the ...